Proactiveinvestors recommends
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
EPIC: BII
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Biocompatibles
www.biocompatibles.com

Biocompatibles International plc is a leading company in the field of drug-device combination products.  The Oncology Products Division conducts the marketing of Biocompatibles’ approved oncology products.  These include products that are used for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and prostate cancer.  Our R&D Facilities are engaged in licensing and in new product development for oncology, stroke, and diabetes and obesity.  We have collaborative agreements with AstraZeneca, Bayer Healthcare Pharmaceuticals Inc. and Medtronic Inc.

Full Biocompatibles profile here
Pdf

Biocompatibles reports positive results from liver cancer patient trial

28th Apr 2009, 9:03 am Biocompatibles reports positive results from liver cancer patient trial

Biocompatibles International PLC (LSE: BII) said a trial of its drug-eluting bead in primary liver cancer patients showed a tumour response rate of 90 percent at six months and adverse events within expected limits.

The trial was conducted at Johns Hopkins University School of Medicine in Baltimore, Maryland, under Professor Jean-Francois Geschwind, Professor of Radiology, Surgery and Oncology.  It involved 20 patients with hepatocellular carcinoma, or HCC.

Professor Geschwind is now recruiting patients in a single arm Phase II trial evaluating the potential usefulness of sorafenib in conjunction with treatment with drug-eluting bead in 50 patients with HCC. Four patients have been treated and it is expected that preliminary data will be presented during the course of 2009. This trial is part of a clinical collaboration agreement between Biocompatibles and Bayer Pharmaceuticals Inc.

He is also recruiting patients in a 30 patient single arm trial evaluating the potential usefulness of the drug-eluting beads in patients with Neuroendocrine Metastases in the liver.

Professor Robert Martin, Associate Professor of Surgery in the Division of Surgical Oncology at the University of Louisville, has initiated a randomised trial for the evaluation of the Drug-Eluting Beads in hepatic colorectal metastases for patients who are not eligible for surgical resection (first line patients). The trial was announced mid-April 2009 and is known as PARAGON Louisville.

Professor Wells Messersmith, Associate Professor, Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO, is recruiting patients with hepatic colorectal metastases who have failed one line of drug therapy (second line patients). This trial is known as PARAGON 1.

Biocpompatibles chief executive Crispin Simon said: "Our drug-eluting bead products are now routinely used in more than 35 countries; but we are maintaining our commitment to assembling definitive evidence in support of this evolution in clinical practice."

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.